Wolverine Trading, LLC Ardelyx, Inc. Call Options Transaction History

Wolverine Trading, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$5.28 - $7.57 $18,480 - $26,495	3,500 Added 7.81%	48,300 $332,000
Q2 2024 Aug 14, 2024	SELL	$5.89 - $9.31 $211,451 - $334,229	-35,900 Reduced 44.49%	44,800 $331,000
Q1 2024 May 15, 2024	SELL	$6.05 - $9.74 $13,310 - $21,428	-2,200 Reduced 2.65%	80,700 $589,000
Q4 2023 Feb 14, 2024	BUY	$3.29 - $6.64 $54,285 - $109,560	16,500 Added 24.85%	82,900 $513,000
Q3 2023 Nov 15, 2023	SELL	$3.3 - $4.83 $38,610 - $56,511	-11,700 Reduced 14.98%	66,400 $270,000
Q2 2023 Aug 23, 2023	SELL	$3.23 - $4.95 $11,305 - $17,325	-3,500 Reduced 4.29%	78,100 $264,000
Q1 2023 May 15, 2023	BUY	$2.68 - $4.79 $24,656 - $44,068	9,200 Added 12.71%	81,600 $375,000
Q4 2022 Feb 14, 2023	BUY	$1.22 - $2.85 $88,328 - $206,340	72,400 New	72,400 $206,000
Q2 2022 Aug 15, 2022	SELL	$0.51 - $1.17 $1,785 - $4,094	-3,500 Reduced 7.48%	43,300 $25,000
Q1 2022 May 16, 2022	BUY	$0.65 - $1.18 $30,420 - $55,224	46,800 New	46,800 $51,000

218

141M

1.08M

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $787M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.